Dr. Martens (LON:DOCS) Insider Giles Wilson Acquires 219 Shares

Dr. Martens plc (LON:DOCS) insider Giles Wilson acquired 219 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were purchased at an average price of GBX 69 per share, for a total transaction of £151.11.

Giles Wilson also recently made the following trade(s):

• On Tuesday, January 13th, Giles Wilson bought 192 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 78 per share, with a total value of £149.76.
• On Thursday, December 11th, Giles Wilson purchased 197 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 76 per share, with a total value of £149.72.

Dr. Martens Stock Performance

DOCS stock opened at GBX 68.35 on Friday. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The firm has a market cap of £660.66 million, a P/E ratio of 40.21, a P/E/G ratio of 6.40 and a beta of 0.11. Dr. Martens plc has a 12-month low of GBX 43.02 and a 12-month high of GBX 100.87. The stock’s 50 day simple moving average is GBX 74.09 and its 200 day simple moving average is GBX 82.27.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, equities research analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DOCS. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Dr. Martens in a research note on Tuesday, February 3rd. Berenberg Bank reaffirmed a “buy” rating on shares of Dr. Martens in a report on Tuesday, January 27th. Finally, Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.